These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 31641082)

  • 21. Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.
    Chen YQ; Wohlbold TJ; Zheng NY; Huang M; Huang Y; Neu KE; Lee J; Wan H; Rojas KT; Kirkpatrick E; Henry C; Palm AE; Stamper CT; Lan LY; Topham DJ; Treanor J; Wrammert J; Ahmed R; Eichelberger MC; Georgiou G; Krammer F; Wilson PC
    Cell; 2018 Apr; 173(2):417-429.e10. PubMed ID: 29625056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.
    Wohlbold TJ; Chromikova V; Tan GS; Meade P; Amanat F; Comella P; Hirsh A; Krammer F
    J Virol; 2016 Jan; 90(2):851-61. PubMed ID: 26512088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.
    Ranadheera C; Hagan MW; Leung A; Collignon B; Cutts T; Theriault S; Embury-Hyatt C; Kobasa D
    J Virol; 2016 Nov; 90(21):9931-9941. PubMed ID: 27558428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies.
    Kosik I; Angeletti D; Gibbs JS; Angel M; Takeda K; Kosikova M; Nair V; Hickman HD; Xie H; Brooke CB; Yewdell JW
    J Exp Med; 2019 Feb; 216(2):304-316. PubMed ID: 30683737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the anti-neuraminidase activity of the traditional Chinese medicines and determination of the anti-influenza A virus effects of the neuraminidase inhibitory TCMs in vitro and in vivo.
    Tian L; Wang Z; Wu H; Wang S; Wang Y; Wang Y; Xu J; Wang L; Qi F; Fang M; Yu D; Fang X
    J Ethnopharmacol; 2011 Sep; 137(1):534-42. PubMed ID: 21699971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice.
    Takahashi E; Sawabuchi T; Kimoto T; Sakai S; Kido H
    J Dairy Sci; 2019 Nov; 102(11):9559-9569. PubMed ID: 31495632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo.
    Edgar JE; Trezise S; Anthony RM; Krammer F; Palese P; Ravetch JV; Bournazos S
    Proc Natl Acad Sci U S A; 2023 Oct; 120(44):e2314905120. PubMed ID: 37871218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.
    Wilson JR; Guo Z; Reber A; Kamal RP; Music N; Gansebom S; Bai Y; Levine M; Carney P; Tzeng WP; Stevens J; York IA
    Antiviral Res; 2016 Nov; 135():48-55. PubMed ID: 27713074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccine-associated enhanced respiratory disease is influenced by haemagglutinin and neuraminidase in whole inactivated influenza virus vaccines.
    Rajão DS; Chen H; Perez DR; Sandbulte MR; Gauger PC; Loving CL; Shanks GD; Vincent A
    J Gen Virol; 2016 Jul; 97(7):1489-1499. PubMed ID: 27031847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies.
    Zhu X; Turner HL; Lang S; McBride R; Bangaru S; Gilchuk IM; Yu W; Paulson JC; Crowe JE; Ward AB; Wilson IA
    Cell Host Microbe; 2019 Dec; 26(6):729-738.e4. PubMed ID: 31757767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase.
    Ramos KE; Okba NMA; Tan J; Bandawane P; Meade PS; Loganathan M; Francis B; Shulenin S; Holtsberg FW; Aman MJ; McMahon M; Krammer F; Lai JR
    mBio; 2024 Jul; 15(7):e0108524. PubMed ID: 38899870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lactococcus lactis displayed neuraminidase confers cross protective immunity against influenza A viruses in mice.
    Lei H; Peng X; Zhao D; Ouyang J; Jiao H; Shu H; Ge X
    Virology; 2015 Feb; 476():189-195. PubMed ID: 25546254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.
    Eichelberger MC; Monto AS
    J Infect Dis; 2019 Apr; 219(Suppl_1):S75-S80. PubMed ID: 30715357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase.
    Yoshikawa T; Suzuki Y; Nomoto A; Sata T; Kurata T; Tamura Si
    Vaccine; 2002 Nov; 21(1-2):60-6. PubMed ID: 12443663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological and protective properties of immune sera directed to the influenza virus neuraminidase.
    Halbherr SJ; Ludersdorfer TH; Ricklin M; Locher S; Berger Rentsch M; Summerfield A; Zimmer G
    J Virol; 2015 Feb; 89(3):1550-63. PubMed ID: 25392225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral activity of puerarin as potent inhibitor of influenza virus neuraminidase.
    Wang HX; Zeng MS; Ye Y; Liu JY; Xu PP
    Phytother Res; 2021 Jan; 35(1):324-336. PubMed ID: 32757226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of the Recombinant Influenza Neuraminidase Antigen Is Crucial for Its Biochemical Properties and Protective Efficacy.
    Gao J; Klenow L; Parsons L; Malik T; Phue JN; Gao Z; Withers SG; Cipollo J; Daniels R; Wan H
    J Virol; 2021 Nov; 95(24):e0116021. PubMed ID: 34613807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.
    Takahashi Y; Hasegawa H; Hara Y; Ato M; Ninomiya A; Takagi H; Odagiri T; Sata T; Tashiro M; Kobayashi K
    J Infect Dis; 2009 Jun; 199(11):1629-37. PubMed ID: 19385735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers.
    Wan H; Yang H; Shore DA; Garten RJ; Couzens L; Gao J; Jiang L; Carney PJ; Villanueva J; Stevens J; Eichelberger MC
    Nat Commun; 2015 Feb; 6():6114. PubMed ID: 25668439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.